Hui Kenrie P Y, Kuok Denise I T, Kang Sara S R, Li Hung-Sing, Ng Mandy M T, Bui Christine H T, Peiris J S Malik, Chan Renee W Y, Chan Michael C W
Centre of Influenza Research, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Centre of Influenza Research, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
Antiviral Res. 2015 Jul;119:1-7. doi: 10.1016/j.antiviral.2015.04.005. Epub 2015 Apr 13.
Highly pathogenic H5N1 viruses continue to transmit zoonotically, with mortality higher than 60%, and pose a pandemic threat. Antivirals remain the primary choice for treating H5N1 diseases and have their limitations. Encouraging findings highlight the beneficial effects of combined treatment of host targeting agents with immune-modulatory activities. This study evaluated the undefined roles of sterol metabolic pathway in viral replication and cytokine induction by H5N1 virus in human alveolar epithelial cells. The suppression of the sterol biosynthesis by Simvastatin in human alveolar epithelial cells led to reduction of virus replication and cytokine production by H5N1 virus. We further dissected the antiviral role of different regulators of the sterol metabolism, we showed that Zometa, FPT inhibitor III, but not GGTI-2133 had anti-viral activities against both H5N1 and H1N1 viruses. More importantly, FPT inhibitor III treatment significantly suppressed cytokine production by H5N1 virus infected alveolar epithelial cells. Since both viral replication itself and the effects of viral hyper-induction of cytokines contribute to the immunopathology of severe H5N1 disease, our findings highlights the therapeutic potential of FPT inhibitor III for severe human H5N1 diseases. Furthermore, our study is the first to dissect the roles of different steps in the sterol metabolic pathway in H5N1 virus replication and cytokine production.
高致病性H5N1病毒继续以人畜共患病的方式传播,死亡率高于60%,并构成大流行威胁。抗病毒药物仍然是治疗H5N1疾病的主要选择,但存在局限性。令人鼓舞的研究结果突出了具有免疫调节活性的宿主靶向药物联合治疗的有益效果。本研究评估了固醇代谢途径在H5N1病毒在人肺泡上皮细胞中的病毒复制和细胞因子诱导中的未知作用。辛伐他汀对人肺泡上皮细胞中固醇生物合成的抑制导致H5N1病毒的病毒复制和细胞因子产生减少。我们进一步剖析了固醇代谢不同调节因子的抗病毒作用,结果表明,唑来膦酸、FPT抑制剂III而非GGTI-2133对H5N1和H1N1病毒均具有抗病毒活性。更重要的是,FPT抑制剂III处理显著抑制了H5N1病毒感染的肺泡上皮细胞的细胞因子产生。由于病毒复制本身以及病毒对细胞因子的过度诱导作用均促成了严重H5N1疾病的免疫病理学,我们的研究结果突出了FPT抑制剂III对严重人类H5N1疾病的治疗潜力。此外,我们的研究首次剖析了固醇代谢途径中不同步骤在H5N1病毒复制和细胞因子产生中的作用。